



ViatriS Announces Quarterly Dividend

May 5, 2026

PITTSBURGH, May 5, 2026 /PRNewswire/ -- [ViatriS Inc.](#) (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of \$0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026.

About ViatriS

[ViatriS Inc.](#) (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at [viatriS.com](#) and [investor.viatriS.com](#), and connect with us on [LinkedIn](#), [Instagram](#), [YouTube](#) and [X](#).

Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that the ViatriS Board declared a quarterly dividend of \$0.12 per share for each issued and outstanding share of the Company's common stock, payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: failure to achieve the intended benefits of our strategic initiatives and priorities; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; failure to achieve expected or targeted future financial and operating performance and results; ViatriS' or its partners' ability to develop, manufacture, and commercialize products; any regulatory, legal or other impediments to ViatriS' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on ViatriS; any significant breach of data security or data privacy or disruptions to our IT systems; risks associated with international operations; changes in third-party relationships; the effect of any changes in ViatriS' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of ViatriS or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in ViatriS' filings with the Securities and Exchange Commission ("SEC"). ViatriS routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). ViatriS undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/viatriS-announces-quarterly-dividend-302761854.html>

SOURCE ViatriS Inc.

MEDIA: +1.724.514.1968; Communications@viatriS.com; Jennifer Mauer, Jennifer.Mauer@viatriS.com; Matt Klein, Matthew.Klein@viatriS.com;
INVESTORS: Bill Szablewski, +1.412.707.2866, InvestorRelations@viatriS.com, William.Szablewski@viatriS.com